Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 122 participants.

Also called NCT04191330

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 122 participants (enrolled count) (from the registry)
Sponsor
Biofourmis Inc. (from the registry)
Registry
  • NCT NCT04191330
Other papers using this trial's data
  • Digital Platform to Optimize Guideline-Directed Heart Failure Therapy: Results of the AIM-POWER Trial Circulation. Heart failure, 2026-02 DOI, PubMed 41332416

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04191330. Randomized; no masking; primary purpose treatment. Start 2020-01-27 (actual); primary completion 2024-06-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors
Acronym
AIM-POWER
Condition
Heart Failure
Intervention (Device)
BiovitalsHF
Lead sponsor
Biofourmis Inc. (class: industry)

Record details

Record id
cardio:ct-nct04191330
Content hash
cd3b01583ae42d0dac4909a413d6edf77a5eff8d33154ae54b4c9e5cab5e325c